Published in Clin Microbiol Rev on January 01, 2002
Pathogenic potential of novel Chlamydiae and diagnostic approaches to infections due to these obligate intracellular bacteria. Clin Microbiol Rev (2006) 1.62
Detection of 11 common viral and bacterial pathogens causing community-acquired pneumonia or sepsis in asymptomatic patients by using a multiplex reverse transcription-PCR assay with manual (enzyme hybridization) or automated (electronic microarray) detection. J Clin Microbiol (2008) 1.51
In-house nucleic acid amplification assays in research: how much quality control is needed before one can rely upon the results? J Clin Microbiol (2005) 1.33
Comparison of a new quantitative ompA-based real-Time PCR TaqMan assay for detection of Chlamydia pneumoniae DNA in respiratory specimens with four conventional PCR assays. J Clin Microbiol (2003) 1.21
Association of circulating Chlamydia pneumoniae DNA with cardiovascular disease: a systematic review. BMC Infect Dis (2002) 1.09
Involvement of Chlamydia pneumoniae in atherosclerosis: more evidence for lack of evidence. J Clin Microbiol (2005) 1.08
Chlamydia pneumoniae infection promotes a proliferative phenotype in the vasculature through Egr-1 activation in vitro and in vivo. Proc Natl Acad Sci U S A (2005) 1.00
Reliability of nested PCR for detection of Chlamydia pneumoniae DNA in atheromas: results from a multicenter study applying standardized protocols. J Clin Microbiol (2002) 1.00
Chlamydophila pneumoniae infection and cardiovascular disease. N Am J Med Sci (2013) 0.95
Immunohistostaining assays for detection of Chlamydia pneumoniae in atherosclerotic arteries indicate cross-reactions with nonchlamydial plaque constituents. J Clin Microbiol (2004) 0.89
Chlamydia pneumoniae infection in atherosclerotic lesion development through oxidative stress: a brief overview. Int J Mol Sci (2013) 0.88
Persistent Chlamydia pneumoniae infection of cardiomyocytes is correlated with fatal myocardial infarction. Am J Pathol (2007) 0.86
Comparative Seroepidemiologic Analysis of Chlamydophila Pneumoniae Infection using Microimmunofluorescence, Enzyme Immunoassay and Neutralization Test: Implications for Serodiagnosis. Indian J Microbiol (2011) 0.84
Chlamydia pneumoniae infection and Alzheimer's disease: a connection to remember? Med Microbiol Immunol (2010) 0.84
Is the perceived association between Chlamydia pneumoniae and vascular diseases biased by methodology? J Clin Microbiol (2004) 0.84
Prevalence and persistence of Chlamydia pneumoniae antibodies in healthy laboratory personnel in Finland. Clin Diagn Lab Immunol (2005) 0.84
Comparison of quantitative and semiquantitative enzyme-linked immunosorbent assays for immunoglobulin G against Chlamydophila pneumoniae to a microimmunofluorescence test for use with patients with respiratory tract infections. J Clin Microbiol (2004) 0.83
Viral and bacterial DNA in carotid atherosclerotic lesions. Eur J Clin Microbiol Infect Dis (2003) 0.83
Effect of clarithromycin treatment on Chlamydia pneumoniae in vascular tissue of patients with coronary artery disease: a randomized, double-blind, placebo-controlled trial. J Clin Microbiol (2005) 0.83
Chlamydophila pneumoniae Infection and Its Role in Neurological Disorders. Interdiscip Perspect Infect Dis (2010) 0.83
Detection of Chlamydia pneumoniae-specific antibodies binding to the VD2 and VD3 regions of the major outer membrane protein. J Clin Microbiol (2003) 0.82
Effects of fluoroquinolones on the migration of human phagocytes through Chlamydia pneumoniae-infected and tumor necrosis factor alpha-stimulated endothelial cells. Antimicrob Agents Chemother (2004) 0.82
Atherosclerosis in young Brazilians suffering violent deaths: a pathological study. BMC Res Notes (2011) 0.81
Qualitative and quantitative detection of Chlamydophila pneumoniae DNA in cerebrospinal fluid from multiple sclerosis patients and controls. PLoS One (2009) 0.81
Infection of human monocytes by Chlamydia pneumoniae and Chlamydia trachomatis: an in vitro comparative study. BMC Res Notes (2014) 0.81
Evaluation of five DNA extraction methods for purification of DNA from atherosclerotic tissue and estimation of prevalence of Chlamydia pneumoniae in tissue from a Danish population undergoing vascular repair. BMC Microbiol (2003) 0.80
Is C. Pneumoniae research in peril? Front Microbiol (2011) 0.80
Chlamydia pneumoniae seropositivity and risk of ischemic stroke: a nested case-control study. Eur J Epidemiol (2005) 0.79
Chlamydia pneumoniae-Mediated Inflammation in Atherosclerosis: A Meta-Analysis. Mediators Inflamm (2015) 0.79
Presence of Chlamydia pneumoniae in patients with and without atherosclerosis. Eur J Clin Microbiol Infect Dis (2005) 0.78
Genetic and culture-based approaches for detecting macrolide resistance in Chlamydia pneumoniae. Antimicrob Agents Chemother (2004) 0.78
Infectious and coronary artery disease. ARYA Atheroscler (2016) 0.77
Absence of Chlamydia pneumoniae and signs of atherosclerotic cardiovascular disease in adolescents with systemic lupus erythematosus. Pediatr Cardiol (2007) 0.77
The case for developing consensus standards for research in microbial pathogenesis: Bacillus anthracis toxins as an example. Infect Immun (2009) 0.77
Chlamydia pneumoniae decreases smooth muscle cell proliferation through induction of prostaglandin E2 synthesis. Infect Immun (2004) 0.77
Chlamydia in canine or feline coronary arteriosclerotic lesions. BMC Res Notes (2011) 0.76
Persistent Chlamydophila pneumoniae infection in thoracic aortic aneurysm and aortic dissection? Ups J Med Sci (2010) 0.75
Anti-chlamydial IgG Neutralizing Ability in Nonzoonotic Atypical Community Acquired Respiratory Tract Infections. Indian J Microbiol (2015) 0.75
Chlamydia pneumoniae-induced memory CD4+ T-cell activation in human peripheral blood correlates with distinct antibody response patterns. Clin Vaccine Immunol (2010) 0.75
A population based seroepidemiological survey of Chlamydia pneumoniae infections in schoolchildren. J Clin Pathol (2005) 0.75
Helicobacter pylori gastritis, a presequeale to coronary plaque. Clin Pract (2015) 0.75
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med (1997) 18.85
Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet (1988) 7.59
Chronic infections and coronary heart disease: is there a link? Lancet (1997) 7.18
A new respiratory tract pathogen: Chlamydia pneumoniae strain TWAR. J Infect Dis (1990) 6.52
Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ (2000) 6.10
Chronic Chlamydia pneumoniae infection as a risk factor for coronary heart disease in the Helsinki Heart Study. Ann Intern Med (1992) 5.65
Randomised trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS Pilot Study. ROXIS Study Group. Lancet (1997) 5.44
Antibiotics and risk of subsequent first-time acute myocardial infarction. JAMA (1999) 5.37
Demonstration of Chlamydia pneumoniae in atherosclerotic lesions of coronary arteries. J Infect Dis (1993) 4.02
Association of Chlamydia pneumoniae (strain TWAR) infection with wheezing, asthmatic bronchitis, and adult-onset asthma. JAMA (1991) 3.99
Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple Risk Factor Intervention Trial. Am J Epidemiol (1996) 3.82
Persistent infection with Chlamydia pneumoniae following acute respiratory illness. Clin Infect Dis (1992) 3.30
Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation (1997) 2.95
Detection of Chlamydia pneumoniae TWAR in human coronary atherectomy tissues. J Infect Dis (1995) 2.90
Isolation of Chlamydia pneumoniae from the coronary artery of a patient with coronary atherosclerosis. The Chlamydia pneumoniae/Atherosclerosis Study Group. Ann Intern Med (1996) 2.72
Standardizing Chlamydia pneumoniae assays: recommendations from the Centers for Disease Control and Prevention (USA) and the Laboratory Centre for Disease Control (Canada). Clin Infect Dis (2001) 2.71
Association of prior infection with Chlamydia pneumoniae and angiographically demonstrated coronary artery disease. JAMA (1992) 2.61
Chlamydia pneumoniae IgG titres and coronary heart disease: prospective study and meta-analysis. BMJ (2000) 2.56
Circulating Chlamydia pneumoniae DNA as a predictor of coronary artery disease. J Am Coll Cardiol (1999) 2.47
Mycoplasma pneumoniae and Chlamydia pneumoniae in pediatric community-acquired pneumonia: comparative efficacy and safety of clarithromycin vs. erythromycin ethylsuccinate. Pediatr Infect Dis J (1995) 2.44
Chlamydia pneumoniae infection in circulating human monocytes is refractory to antibiotic treatment. Circulation (2001) 2.36
Detection of Chlamydia pneumoniae in coronary arterial fatty streaks and atheromatous plaques. S Afr Med J (1992) 2.28
Detection of Chlamydia pneumoniae in aortic lesions of atherosclerosis by immunocytochemical stain. Arterioscler Thromb (1993) 2.27
Chlamydia pneumoniae (TWAR) in atherosclerosis of the carotid artery. Circulation (1995) 2.24
A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia. Antimicrob Agents Chemother (1997) 2.19
Interactive role of infection, inflammation and traditional risk factors in atherosclerosis and coronary artery disease. J Am Coll Cardiol (1998) 2.16
Chlamydia pneumoniae (TWAR) in coronary arteries of young adults (15-34 years old). Proc Natl Acad Sci U S A (1995) 2.15
Endovascular presence of viable Chlamydia pneumoniae is a common phenomenon in coronary artery disease. J Am Coll Cardiol (1998) 2.12
Failure to detect Chlamydia pneumoniae in coronary atheromas of patients undergoing atherectomy. J Infect Dis (1996) 2.12
A seroepidemiologic study of Chlamydia pneumoniae in Rhode Island. Evidence of serologic cross-reactivity. Chest (1993) 2.09
Serological cross-reactions between Bartonella and Chlamydia species: implications for diagnosis. J Clin Microbiol (1997) 2.08
Isolation of Chlamydia pneumoniae from a carotid endarterectomy specimen. J Infect Dis (1997) 2.06
Treatment with the antibiotic roxithromycin in patients with acute non-Q-wave coronary syndromes. The final report of the ROXIS Study. Eur Heart J (1999) 1.92
Baseline IgG antibody titers to Chlamydia pneumoniae, Helicobacter pylori, herpes simplex virus, and cytomegalovirus and the risk for cardiovascular disease in women. Ann Intern Med (1999) 1.91
Low prevalence of Chlamydia pneumoniae in atherectomy specimens from patients with coronary heart disease. Clin Infect Dis (1999) 1.91
Ofloxacin treatment of Chlamydia pneumoniae (strain TWAR) lower respiratory tract infections. Am J Med (1990) 1.86
Prevalence of asymptomatic nasopharyngeal carriage of Chlamydia pneumoniae in subjectively healthy adults: assessment by polymerase chain reaction-enzyme immunoassay and culture. Clin Infect Dis (1995) 1.86
Infection with Chlamydia pneumoniae accelerates the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit model. Circulation (1998) 1.86
Chlamydia pneumoniae strain TWAR antibody and angiographically demonstrated coronary artery disease. Arterioscler Thromb (1991) 1.86
Infectious agents are not necessary for murine atherogenesis. J Exp Med (2000) 1.85
Cellular pathology. As based upon physiological and pathological histology. Lecture XVI--Atheromatous affection of arteries. 1858. Nutr Rev (1989) 1.84
Association of Chlamydia pneumoniae and acute coronary heart disease events in non-insulin dependent diabetic and non-diabetic subjects in Finland. Eur Heart J (1996) 1.82
Specificity of the microimmunofluorescence assay for the serodiagnosis of Chlamydia pneumoniae infections. Can J Microbiol (1992) 1.77
Randomized secondary prevention trial of azithromycin in patients with coronary artery disease: primary clinical results of the ACADEMIC study. Circulation (2000) 1.74
Chlamydia pneumoniae, cytomegalovirus, and herpes simplex virus in atherosclerosis of the carotid artery. Circulation (1997) 1.74
The emergence of Streptococcus pneumoniae resistant to macrolide antimicrobial agents: a 6-year population-based assessment. J Infect Dis (2000) 1.69
Detection of Chlamydia pneumoniae but not Helicobacter pylori in atherosclerotic plaques of aortic aneurysms. J Clin Microbiol (1996) 1.68
Chlamydia pneumoniae in arteries: the facts, their interpretation, and future studies. J Clin Pathol (1998) 1.64
High prevalence of Chlamydia pneumoniae DNA in peripheral blood mononuclear cells in patients with cardiovascular disease and in middle-aged blood donors. J Infect Dis (1998) 1.61
Microbiologic efficacy of azithromycin and susceptibilities to azithromycin of isolates of Chlamydia pneumoniae from adults and children with community-acquired pneumonia. Antimicrob Agents Chemother (1998) 1.60
The proatherogenic properties of lipoprotein(a) may be enhanced through the formation of circulating immune complexes containing Chlamydia pneumoniae-specific IgG antibodies. Eur Heart J (2000) 1.57
Increased incidence of Chlamydia species within the coronary arteries of patients with symptomatic atherosclerotic versus other forms of cardiovascular disease. J Am Coll Cardiol (1996) 1.55
Nucleotide sequence and taxonomic value of the major outer membrane protein gene of Chlamydia pneumoniae IOL-207. J Gen Microbiol (1991) 1.53
Molecular diagnosis of Chlamydia pneumoniae infection. J Clin Microbiol (1999) 1.52
Detection and widespread distribution of Chlamydia pneumoniae in the vascular system and its possible implications. J Clin Pathol (1996) 1.49
The prevalence of Chlamydia pneumoniae in atherosclerotic and nonatherosclerotic blood vessels of patients attending for redo and first time coronary artery bypass graft surgery. J Am Coll Cardiol (1999) 1.48
The species specificity of the microimmunofluorescence antibody test and comparisons with a time resolved fluoroscopic immunoassay for measuring IgG antibodies against Chlamydia pneumoniae. J Clin Pathol (1999) 1.46
Multicenter comparison trial of DNA extraction methods and PCR assays for detection of Chlamydia pneumoniae in endarterectomy specimens. J Clin Microbiol (2001) 1.46
Past infection by Chlamydia pneumoniae strain TWAR and asymptomatic carotid atherosclerosis. Atherosclerosis Risk in Communities (ARIC) Study Investigators. Am J Med (1993) 1.44
Chlamydia pneumoniae does not influence atherosclerotic plaque behavior in patients with established carotid artery stenosis. Stroke (2000) 1.43
In vitro activity of a new ketolide antibiotic, HMR 3647, against Chlamydia pneumoniae. Antimicrob Agents Chemother (1998) 1.36
Chlamydia pneumoniae serology: interlaboratory variation in microimmunofluorescence assay results. J Infect Dis (2000) 1.36
Susceptibilities to clarithromycin and erythromycin of isolates of Chlamydia pneumoniae from children with pneumonia. Antimicrob Agents Chemother (1994) 1.32
Inflammation, infection, and cardiovascular risk: how good is the clinical evidence? Circulation (1998) 1.31
Chlamydia pneumoniae DNA detection in peripheral blood mononuclear cells is predictive of vascular infection. J Infect Dis (1999) 1.30
Comparison of five serologic tests for diagnosis of acute infections by Chlamydia pneumoniae. Clin Diagn Lab Immunol (2000) 1.30
Prospective study of Chlamydia pneumoniae IgG seropositivity and risks of future myocardial infarction. Circulation (1999) 1.29
Age-related interference with Chlamydia pneumoniae microimmunofluorescence serology due to circulating rheumatoid factor. J Clin Microbiol (1992) 1.26
Specificity of detection of Chlamydia pneumoniae in cardiovascular atheroma: evaluation of the innocent bystander hypothesis. Am J Pathol (1997) 1.24
The microimmunofluorescence test for Chlamydia pneumoniae infection: technique and interpretation. J Infect Dis (2000) 1.24
Chlamydia pneumoniae is a risk factor for coronary heart disease in symptom-free elderly men, but Helicobacter pylori and cytomegalovirus are not. Epidemiol Infect (1998) 1.24
Chlamydia pneumoniae, herpes simplex virus type 1, and cytomegalovirus and incident myocardial infarction and coronary heart disease death in older adults : the Cardiovascular Health Study. Circulation (2000) 1.22
Safety and efficacy of azithromycin in the treatment of community-acquired pneumonia in children. Pediatr Infect Dis J (1998) 1.21
In vitro activities of azithromycin and ofloxacin against Chlamydia pneumoniae in a continuous-infection model. Antimicrob Agents Chemother (1999) 1.20
Microbiologic efficacy of moxifloxacin for the treatment of community-acquired pneumonia due to Chlamydia pneumoniae. Int J Antimicrob Agents (2000) 1.15
Confirmed previous infection with Chlamydia pneumoniae (TWAR) and its presence in early coronary atherosclerosis. Circulation (1998) 1.15
In vitro activity of a group of broad-spectrum cephalosporins and other beta-lactam antibiotics against Chlamydia trachomatis. Antimicrob Agents Chemother (1983) 1.14
Frequency of serological evidence of Bordetella infections and mixed infections with other respiratory pathogens in university students with cough illnesses. Clin Infect Dis (2000) 1.13
Endovascular presence of Chlamydia pneumoniae in patients with hemodynamically effective carotid artery stenosis. Angiology (1997) 1.12
Comparative anti-inflammatory effects of roxithromycin, azithromycin and clarithromycin. J Antimicrob Chemother (1998) 1.11
Demonstration of Chlamydia pneumoniae in the walls of abdominal aortic aneurysms. J Vasc Surg (1997) 1.11
Chlamydia pneumoniae infection and mortality from ischaemic heart disease: large prospective study. BMJ (2000) 1.09
The use of serologic tests for the diagnosis of chlamydial infections. J Microbiol Methods (2000) 1.06
Infections and atherosclerosis: new clues from an old hypothesis? Am J Epidemiol (1998) 1.06
Can acute Chlamydia pneumoniae respiratory tract infection initiate chronic asthma? Ann Allergy Asthma Immunol (1998) 1.06
Detection of Chlamydia pneumoniae within peripheral blood monocytes of patients with unstable angina or myocardial infarction. J Infect Dis (2000) 1.06
Chlamydia pneumoniae in human abdominal aortic aneurysms. Eur J Vasc Endovasc Surg (1998) 1.05
Relation between direct detection of Chlamydia pneumoniae DNA in human coronary arteries at postmortem examination and histological severity (Stary grading) of associated atherosclerotic plaque. Circulation (1999) 1.04
Chronic infection with Helicobacter pylori, Chlamydia pneumoniae, or cytomegalovirus: population based study of coronary heart disease. Heart (1999) 1.04
Failure to detect Chlamydia pneumoniae in atherosclerotic plaques of Australian patients. Pathology (1998) 1.03
Chlamydia pneumoniae in vascular tissues from heart-transplant donors. Lancet (1998) 1.03
Failure to demonstrate Chlamydia pneumoniae in symptomatic abdominal aortic aneurysms by a nested polymerase chain reaction (PCR). Eur J Vasc Endovasc Surg (1998) 1.02
Detection of Chlamydia pneumoniae in atherosclerotic plaques in the walls of arteries of lower extremities from patients undergoing bypass operation for arterial obstruction. J Vasc Surg (1997) 1.02
Detection of Chlamydia pneumoniae DNA and antigen in the circulating mononuclear cell fractions of humans and koalas. Infect Immun (2000) 1.02
Evaluation of C-reactive protein, an inflammatory marker, and infectious serology as risk factors for coronary artery disease and myocardial infarction. J Am Coll Cardiol (1998) 1.00
Demonstration of viable Chlamydia pneumoniae in atherosclerotic plaques of carotid arteries by reverse transcriptase polymerase chain reaction. Ann Vasc Surg (1999) 0.99
Polymerase chain reaction detection of Chlamydia pneumoniae in circulating white blood cells. J Infect Dis (2000) 0.99
Chlamydia pneumoniae infection and incident coronary heart disease: the Atherosclerosis Risk in Communities Study. Am J Epidemiol (1999) 0.99
Infection with Simkania negevensis in Brooklyn, New York. Pediatr Infect Dis J (2005) 1.54
Acute respiratory infection due to Chlamydia pneumoniae: current status of diagnostic methods. Clin Infect Dis (2007) 1.38
In-house nucleic acid amplification assays in research: how much quality control is needed before one can rely upon the results? J Clin Microbiol (2005) 1.33
In vitro activities of BMS-284756 against Chlamydia trachomatis and recent clinical isolates of Chlamydia pneumoniae. Antimicrob Agents Chemother (2002) 1.13
In vitro activity of CEM-101, a new fluoroketolide antibiotic, against Chlamydia trachomatis and Chlamydia (Chlamydophila) pneumoniae. Antimicrob Agents Chemother (2009) 1.07
In vitro activities of rifamycin derivatives ABI-1648 (Rifalazil, KRM-1648), ABI-1657, and ABI-1131 against Chlamydia trachomatis and recent clinical isolates of Chlamydia pneumoniae. Antimicrob Agents Chemother (2003) 1.07
Recurrent intravascular-catheter-related bacteremia caused by Delftia acidovorans in a hemodialysis patient. J Clin Microbiol (2011) 1.05
Infectious causes of multiple sclerosis. Lancet Neurol (2006) 1.04
Emergence of resistance to rifampin and rifalazil in Chlamydophila pneumoniae and Chlamydia trachomatis. Antimicrob Agents Chemother (2005) 1.04
Epidemiology of sexually transmitted infections in suspected child victims of sexual assault. Pediatrics (2009) 1.03
Chlamydia trachomatis as a cause of neonatal conjunctivitis in Dutch infants. Pediatrics (2008) 1.03
Therapeutic approaches to Chlamydia infections. Expert Opin Pharmacother (2005) 1.02
In vitro activity of garenoxacin against recent clinical isolates of Chlamydia pneumoniae. Int J Antimicrob Agents (2003) 0.99
Severe ocular reactions after neonatal ocular prophylaxis with gentamicin ophthalmic ointment. Pediatr Infect Dis J (2011) 0.93
Differential expression of genes encoding membrane proteins between acute and continuous Chlamydia pneumoniae infections. Microb Pathog (2003) 0.92
Effect of prolonged treatment with azithromycin, clarithromycin, or levofloxacin on Chlamydia pneumoniae in a continuous-infection Model. Antimicrob Agents Chemother (2002) 0.92
Treatment of Chlamydial infections: 2014 update. Expert Opin Pharmacother (2015) 0.92
Asthmatic children have increased specific anti-Mycoplasma pneumoniae IgM but not IgG or IgE-values independent of history of respiratory tract infection. Pediatr Infect Dis J (2013) 0.88
Isolation and antimicrobial susceptibilities of Chlamydial isolates from Western barred bandicoots. J Clin Microbiol (2006) 0.88
Molecular characterization of Chlamydophila pneumoniae isolates from Western barred bandicoots. J Med Microbiol (2007) 0.87
Update on fusidic acid (CEM-102) tested against Neisseria gonorrhoeae and Chlamydia trachomatis. Antimicrob Agents Chemother (2010) 0.87
In vitro activity of a new antibiotic, NVP-PDF386 (VRC4887), against Chlamydia pneumoniae. Antimicrob Agents Chemother (2003) 0.86
Overcoming current obstacles in the management of bacterial community-acquired pneumonia in ambulatory children. Clin Pediatr (Phila) (2005) 0.86
Multicenter study of nucleic acid amplification tests for detection of Chlamydia trachomatis and Neisseria gonorrhoeae in children being evaluated for sexual abuse. Pediatr Infect Dis J (2009) 0.85
Sophorolipids as antibacterial agents. Ann Clin Lab Sci (2009) 0.85
Effect of gemifloxacin on viability of Chlamydia pneumoniae (Chlamydophila pneumoniae) in an in vitro continuous infection model. J Antimicrob Chemother (2002) 0.85
The in vitro activity of a new fluoroquinolone, ABT-492, against recent clinical isolates of Chlamydia pneumoniae. J Antimicrob Chemother (2004) 0.85
Minocycline treatment results in reduced oral steroid requirements in adult asthma. Allergy Asthma Proc (2008) 0.85
Anogenital human papillomavirus in sexually abused and nonabused children: a multicenter study. Pediatrics (2011) 0.81
The role of Chlamydia pneumoniae infection in children with chronic sinusitis. Arch Otolaryngol Head Neck Surg (2003) 0.81
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone antibiotic, against Chlamydia trachomatis and Chlamydia pneumoniae. Antimicrob Agents Chemother (2013) 0.80
Genetic and culture-based approaches for detecting macrolide resistance in Chlamydia pneumoniae. Antimicrob Agents Chemother (2004) 0.78
Development of PCR assays for detection of Trichomonas vaginalis in urine specimens. J Clin Microbiol (2013) 0.78
Reliability of nested PCR for the detection of Chlamydia pneumoniae in carotid artery atherosclerosis. Stroke (2003) 0.77
The role of Chlamydia pneumoniae in multiple sclerosis: real or fictitious? J Infect Dis (2005) 0.77
Absence of Chlamydia pneumoniae and signs of atherosclerotic cardiovascular disease in adolescents with systemic lupus erythematosus. Pediatr Cardiol (2007) 0.77
Treatment of vancomycin-resistant Enterococcus faecium ventriculitis in a neonate. Int J Antimicrob Agents (2007) 0.76
Eradication of Chlamydia pneumoniae from coronary artery endothelium. Cardiovasc Drugs Ther (2002) 0.75
Comment on: Gemifloxacin once daily for 5 days versus 7 days for the treatment of community-acquired pneumonia: a randomized, multicentre, double-blind study. J Antimicrob Chemother (2007) 0.75
Testing for gonorrhea. Pediatr Infect Dis J (2003) 0.75
Chlamydia pneumoniae and asthma in children: diagnostic issues. Clin Infect Dis (2004) 0.75
Effect of azithromycin on endothelial function of patients with coronary artery disease and evidence of Chlamydia pneumoniae infection. Circulation (2002) 0.75
Nucleic acid amplification tests (polymerase chain reaction, ligase chain reaction) for the diagnosis of Chlamydia trachomatis and Neisseria gonorrhoeae in pediatric emergency medicine. Pediatr Emerg Care (2005) 0.75
Seroprevalence of Chlamydia trachomatis in Inner-City Children and Adolescents-Implications for Vaccine Development. Sex Transm Dis (2017) 0.75
Spontaneous Escherichia coli cellulitis in a child with nephrotic syndrome. Pediatr Infect Dis J (2007) 0.75
Epigallocatechin gallate suppresses Chlamydia pneumoniae mediated IgE responses in peripheral blood mononuclear cells: a pilot study. Minerva Med (2016) 0.75
Doxycycline suppresses Chlamydia pneumoniae-mediated increases in ongoing immunoglobulin E and interleukin-4 responses by peripheral blood mononuclear cells of patients with allergic asthma. J Antimicrob Chemother (2013) 0.75
In vitro models of acute and long-term continuous infection of human respiratory epithelial cells with Chlamydophila pneumoniae have opposing effects on host cell apoptosis. Microb Pathog (2007) 0.75
Diagnostic Practices for Suspected Community-Acquired Central Nervous System Infection in the Post-Conjugate Vaccine Era. Pediatr Emerg Care (2017) 0.75
Methicillin-resistant Staphylococcus aureus colonization in otitis-prone children. Arch Otolaryngol Head Neck Surg (2011) 0.75
Is Chlamydia pneumoniae infection associated with stroke in children with sickle cell disease? Pediatrics (2004) 0.75